COMMUNIQUÉ DE PRESSE publié le 04/03/2024 à 16:00, il y a 8 mois 16 jours Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
COMMUNIQUÉ DE PRESSE publié le 30/01/2024 à 16:00, il y a 9 mois 21 jours Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
COMMUNIQUÉ DE PRESSE publié le 05/12/2023 à 16:30, il y a 11 mois 15 jours Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
COMMUNIQUÉ DE PRESSE publié le 11/10/2023 à 16:00, il y a 1 année 1 mois Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
COMMUNIQUÉ DE PRESSE publié le 03/10/2023 à 15:15, il y a 1 année 1 mois NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain
Publié le 21/11/2024 à 06:58, il y a 6 heures 39 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 39 minutes Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 39 minutes Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 30 minutes Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 17 minutes Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 21/11/2024 à 13:00, il y a 37 minutes Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 37 minutes Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 37 minutes Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Publié le 21/11/2024 à 13:00, il y a 37 minutes Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Publié le 21/11/2024 à 13:00, il y a 37 minutes Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Publié le 21/11/2024 à 12:35, il y a 1 heure 2 minutes audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 22 minutes Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven